NsGene A/S

NsGene (Ballerup, Denmark) is a clinical-stage biopharmaceutical company committed to developing novel biologics for the treatment of neurological diseases, including Alzheimer’s disease, neuropathic pain, and Parkinson’s disease. To address the challenge of crossing the blood-brain barrier, the company has developed a proprietary, encapsulated cell biodelivery technology – the EC BiodeliveryTM platform. NsGene’s lead product, Neublastin for the treatment of neuropathic pain, has been licensed to Biogen Idec and is currently in clinical phase I.

Sten Verland


Mobile: +45 24 22 19 69
Email Click here to contact